agilon health (AGL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
2 Jun, 2026Opening remarks and agenda
Emphasis on long-term value creation, strategic engagement, and operational execution as priorities for the board and management in 2025 and into 2026.
Introduction of board members, management team, independent auditor, legal counsel, and inspector of election.
Board and executive committee updates
Board remains aligned with management, providing guidance and oversight to ensure strategic priorities and sustainable results.
CEO Tim O'Rourke introduced, highlighting his experience and role in advancing mission and strategy.
Shareholder proposals
Three proposals presented: election of three Class II directors, ratification of independent auditors, and advisory approval of executive compensation.
Board recommended voting in favor of all proposals.
Latest events from agilon health
- Profitability surged in Q1 2026, prompting raised full-year guidance for key metrics.AGL
Q1 202613 May 2026 - Tim O'Rourke named CEO and Director with new compensation terms; no changes to voting matters.AGL
Proxy filing27 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.AGL
Proxy filing23 Apr 2026 - Proxy covers director elections, auditor ratification, pay-for-performance, and ESG priorities.AGL
Proxy filing23 Apr 2026 - 2026 guidance targets breakeven EBITDA and $5.5B revenue after cost discipline and transformation.AGL
Q4 20257 Apr 2026 - Shareholders approved a reverse stock split and adjournment proposal, both backed by the Board.AGL
EGM 202617 Mar 2026 - Transformation, data-driven care, and disciplined contracting set the stage for growth and stability.AGL
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Disciplined contracting, cost controls, and clinical programs drive margin gains amid elevated trends.AGL
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Stockholders to vote on a reverse stock split, reducing shares to as low as 16.6 million.AGL
Proxy Filing20 Feb 2026